Average evoked responses (AERs) were recorded simultaneously from 3 hypothalamic nuclei of freely behaving rats. Permanent semi-microelectrodes were implanted 6–8 days before experiments were begun. The amygdaloid AER to 32 successive stimuli consisted of large amplitude potentials made up of 3 components (P1, N1 and P2) with short latencies. The neuronal recovery function (NRF) was short. However, the acoustic AER to 32 successive acoustic stimuli in anterior hypothalamus (AH), ventromedial hypothalamus (VMH), and arcuate nucleus (AN) consisted of large amplitude potentials of long duration made up of 5 components (P1 N1, P2, N2 and P3) with long latencies. The NRF was long. Intraperitoneal administration of L-dopa heightened the amplitude of the acoustic AER and shortened the NRF in VMH and AN. Reserpine administration 2 h after L-dopa maintained these phenomena in VMH and AN without alteration of the AER and NRF in AH. When reserpine was administered first, enhancement of the acoustic AER and shortening of the NRF was again obtained only in VMH and AN. L-dopa injection after reserpine treatment maintained these phenomena. Low doses of pentobarbital after L-dopa and reserpine and vice versa caused a marked increase in the acoustic AER and a shortening of the NRF in all recording sites. The amygdala AER and NRF, however, were not altered by any treatment or in any recording sites.

Keywords:
Freely moving rats, Evoked potential, L-dopa and reserpine, Hypothalamus
This content is only available via PDF.
© 1975 S. Karger AG, Basel
1975
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.